Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel

SIMPLE SUMMARY: In clinical trials, patients treated with idecabtagene vicleucel (ide-cel) chimeric antigen receptor T-cell therapy (CAR T) have reported meaningful improvements in patient-reported outcomes, such as health-related quality of life. To test whether these findings are generalizable to...

Descripción completa

Detalles Bibliográficos
Autores principales: Oswald, Laura B., Gudenkauf, Lisa M., Li, Xiaoyin, De Avila, Gabriel, Peres, Lauren C., Kirtane, Kedar, Gonzalez, Brian D., Hoogland, Aasha I., Nguyen, Oanh, Rodriguez, Yvelise, Baz, Rachid C., Shain, Kenneth H., Alsina, Melissa, Locke, Frederick L., Freeman, Ciara, Castaneda Puglianini, Omar, Nishihori, Taiga, Liu, Hien, Blue, Brandon, Grajales-Cruz, Ariel, Jim, Heather S. L., Hansen, Doris K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571575/
https://www.ncbi.nlm.nih.gov/pubmed/37835405
http://dx.doi.org/10.3390/cancers15194711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571575/
https://www.ncbi.nlm.nih.gov/pubmed/37835405
http://dx.doi.org/10.3390/cancers15194711

Ejemplares similares